• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does Strong Q1 Results And VASCADE Data Shift The Bull Case For Haemonetics (HAE)?

    Simply Wall St·08/11/2026 21:30:31
    Listen to the news
    • In early August 2026, Haemonetics Corporation reported first‑quarter sales of US$339.38 million versus US$321.39 million a year earlier, with diluted earnings per share from continuing operations rising to US$0.72, and also filed a US$391.25 million shelf registration for 4,680,000 common shares tied to an ESOP-related offering.
    • A new Emory University study, published with Haemonetics funding, reinforced the safety and efficiency profile of the VASCADE MVP XL venous vascular closure system in large-bore electrophysiology procedures, supporting its recently expanded U.S. FDA labeling and potential role across leading atrial fibrillation and left atrial appendage closure technologies.
    • We’ll now examine how Haemonetics’ stronger-than-expected quarterly revenue and VASCADE MVP XL data may influence its existing investment narrative.

    This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

    Haemonetics Investment Narrative Recap

    To own Haemonetics, you need to believe its core plasma, hemostasis, and interventional portfolios can keep deepening their role inside hospitals and blood centers, while VASCADE evolves into a more meaningful growth and diversification engine. The recent quarter’s modest sales increase and largely stable earnings do not appear to change that near term. The key catalyst remains execution in Interventional Technologies, particularly VASCADE, while the biggest risk is still product and geographic concentration in the U.S.

    The newly published Emory data on VASCADE MVP XL looks especially relevant here. It strengthens the clinical story behind Haemonetics’ expanded U.S. FDA labeling in large bore electrophysiology procedures, which directly supports the company’s push to make Interventional Technologies a more reliable growth contributor. For investors watching whether VASCADE can offset earlier underperformance and justify its importance in the narrative, this real world evidence is arguably more meaningful than the quarter’s incremental numbers.

    Yet against this backdrop, investors should also recognize how U.S. concentration and intensifying competition could still pressure margins and growth if...

    Read the full narrative on Haemonetics (it's free!)

    Haemonetics' narrative projects $1.5 billion revenue and $247.6 million earnings by 2029. This requires 5.3% yearly revenue growth and a $72.2 million earnings increase from $175.4 million.

    Uncover how Haemonetics' forecasts yield a $86.90 fair value, in line with its current price.

    Exploring Other Perspectives

    HAE 1-Year Stock Price Chart
    HAE 1-Year Stock Price Chart

    Some of the lowest ranked analysts are far more cautious than consensus, assuming revenue only reaches about US$1.6 billion and earnings roughly US$230 million by 2029, so if you worry about reimbursement and competitive headwinds more than most, their view shows how sharply expectations can differ and why this quarter’s VASCADE and earnings news might eventually reshape those pessimistic scenarios.

    Explore 2 other fair value estimates on Haemonetics - why the stock might be worth over 2x more than the current price!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Ready To Venture Into Other Investment Styles?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.